Mice with immobilized legs that received MOTS-c had lower levels of key inflammation markers in their blood compared to untreated mice.
Scientific Claim
In male C57BL/6J mice with 8 days of hindlimb immobilization, daily MOTS-c administration (15 mg/kg/day) was associated with lower plasma levels of interleukin-1β, interleukin-6, CXCL1, and MCP-1 compared to untreated immobilized controls.
Original Statement
“Eight days of cast immobilization dramatically increased plasma levels of IL-1β, IL-6, CXCL1, and MCP-1 (all P < 0.01), whereas MOTS-c treatment partially or completely suppressed the elevation of these cytokine levels (Supplemental Fig. S3, A–D).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
association
Can only show association/correlation
Assessment Explanation
The study design supports association claims. The claim uses 'was associated with' and specifies the model and cytokines without implying causation.
Evidence from Studies
Supporting (1)
Mitochondrial-derived microprotein MOTS-c attenuates immobilization-induced skeletal muscle atrophy by suppressing lipid infiltration.